Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SP2086 (Retagliptin) Monotherapy in Type 2 Diabetes
NCT01970033Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Dec 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of retagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoint: Change From Baseline in Hemoglobin A1c at 24 weeks. Status: unknown.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01970033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01970033.